Hyundai Chae-Jeong announced on the 8th that “the sales of the new lung cancer drug ‘LaserTide’ are expected to expand.” He emphasized that securing U.S. insurance codes and releasing overall survival data could serve as supporting evidence. Along with this, he outlined prospects for AmiBintam and combination therapy, adjusting the previous target price from 120 000 KRW to 110 000 KRW.
Researcher Kim Hyun-seok analyzed that the combination use of LaserTide and AmiBintam has not yet fully achieved overall survival. However, he noted there is still room for improvement, and if data are released, expansion potential could be high. He positively evaluated that in July last year, one monthly purchase order of AmiBintam was secured with a U.S. insurance code.
Another researcher highlighted the potential of the allergy treatment drug ‘Retcherseut,’ announcing that early clinical trial results show it more effectively inhibits IgE antibodies than existing products. The drug is currently undergoing global phase‑2 trials and is expected to be launched later.
In one report, Hyundai Chae-Jeong said its pharmaceutical business was also expanding. Because of U.S. regulatory influence, customer demand for supply increased; they have received three supply contracts this year. Researcher Kim reported that new production lines will start next year, indicating the scale continues to expand.